See more
BioBeats Comparisons
t labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris
BioBeats Signals
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Is BigBear.ai a buy right now?
1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BigBear.ai in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BigBear.ai stock.
Who are some of BigBear.ai's key competitors?
Some companies that are related to BigBear.ai include Magic Software Enterprises (MGIC), Couchbase (BASE), NCC Group (NCCGF), SkillSoft (SKIL), Porch Group (PRCH), Opera (OPRA), Peak Fintech Group (TNT), 2U (TWOU), ON24 (ONTF), TPG Pace Tech Opportunities (NRDY), Karooooo (KARO), American Software (AMSWA), Cognyte Software (CGNT), PLAYSTUDIOS (MYPS) and WM Technology (MAPS). View all of BBAI's competitors..
What is BigBear.ai's stock symbol?
BigBear.ai trades on the New York Stock Exchange (NYSE) under the ticker symbol "BBAI."
Who are BigBear.ai's major shareholders?
BigBear.ai's stock is owned by many different institutional and retail investors. Top institutional shareholders include Glazer Capital LLC (8.39%), Skaana Management L.P. (0.00%), Schonfeld Strategic Advisors LLC (0.17%), Susquehanna International Group LLP (0.00%), Gillson Capital LP (0.09%) and Wolverine Asset Management LLC (0.02%).
Which major investors are buying BigBear.ai stock?
BBAI stock was acquired by a variety of institutional investors in the last quarter, including Glazer Capital LLC, Skaana Management L.P., Schonfeld Strategic Advisors LLC, Susquehanna International Group LLP, Gillson Capital LP, Wolverine Asset Management LLC, and Penserra Capital Management LLC.
How do I buy shares of BigBear.ai?
Shares of BBAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What is BigBear.ai's stock price today?
One share of BBAI stock can currently be purchased for approximately $5.22.
When did Biogen stock close?
FDA (Food and Drug Administration) granted accelerated approval to Aduhelm, its Alzheimer’s disease drug, on June 7. Following the announcement, Biogen stock closed 38% higher on June 7.
What drug did Biogen stock skid?
Biogen stock skidded Wednesday after advisors to the EMA voted against recommending its Alzheimer's drug, Aduhelm, for approval.
Does Biogen stand by the FDA?
Biogen, under pressure, tells investors it ‘stands by’ the FDA review process for its Alzheimer’s drug. Biogen executives sought to assure investors that the science behind its newly approved Alzheimer’s disease drug is firm despite ongoing questions about whether the drug works, how it was approved, and what it costs.
Does Biogen work with the European Medicines Agency?
Biogen says it will continue to engage with the European Medicines Agency and its advisory committee.
Could Advocacy Groups' Campaign for Aduhelm Benefit Biogen?
In this Motley Fool Live video recorded on Jan. 26, 2022, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not these campaigns could benefit Biogen. Keith Speights: Hey, we talked recently about the Centers for Medicare and Medicaid Services, or CMS, opting to pay only for participants in clinical studies evaluating Biogen's Alzheimer's disease drug Aduhelm.
